Overview

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Status:
RECRUITING

Trial end date:
2027-03-31

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib.

Phase:

PHASE2

Details

Lead Sponsor:

Meng Chao Hepatobiliary Hospital of Fujian Medical University